In Brief
Refine Search
Pharmaceutical
UK-based immunotherapy firm Centauri Therapeutics has secured a £1 million ($1.25 million) grant from PACE (Pathways to Antimicrobial Clinical Efficacy) to further develop its Alphamer technology. 25 November 2024
Pharmaceutical
GSK has announced its largest US manufacturing investment to date, dedicated to producing medicines and vaccines. 25 October 2024
Pharmaceutical
Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Pharmaceutical
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
Pharmaceutical
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
Pharmaceutical
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
Pharmaceutical
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
Pharmaceutical
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Pharmaceutical
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Pharmaceutical
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
Pharmaceutical
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Pharmaceutical
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
Pharmaceutical
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
Pharmaceutical
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Pharmaceutical
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Pharmaceutical
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Pharmaceutical
Spanish plasma-derived medicines company Grifols announced with the Andorran government the cancellation of the immunology research center planned for the parish of Ordino. 29 July 2024
Pharmaceutical
The US Food and Drug Administration (FDA) approved Palforzia (peanut [Arachis hypogaea] allergen powder-dnfp] to include initiation of treatment, up-dosing and maintenance in individuals ages one through three years. 27 July 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Pharmaceutical
Japan’s largest drugmaker, Takeda Pharmaceuticals, announced it is working with the European Medicines Agency (EMA) to voluntarily withdraw the marketing authorization of Alofisel (darvadstrocel), a treatment for complex perianal fistulas in patients with Crohn’s disease, in the European Union (EU). 16 December 2024
Pharmaceutical
The schizophrenia market across the seven major markets is poised to grow at a compound annual growth rate (CAGR) of 7.4% from $8.4 billion in 2021 to $17.0 billion in 2031, driven by the anticipated introduction of 11 late-stage pipeline products during the forecast period. 16 December 2024
Pharmaceutical
Denmark-based diabetes and obesity giant Novo Nordisk says it plans to invest 8.5 billion Danish kroner ($1.2 billion) to establish a completely new production facility in Odense, Denmark. 16 December 2024
Pharmaceutical
UK-based PureTech Health has announced positive results from ELEVATE IPF, a Phase IIb trial of deupirfenidone (LYT-100) at two dose levels, three times a day (TID) over 26 weeks in patients with idiopathic pulmonary fibrosis (IPF). 16 December 2024
Pharmaceutical
UK-based NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announced the appointment of Michael Shih as chief executive (CEO) and to the board of directors, effective immediately. 16 December 2024
Pharmaceutical
The pharmaceutical and life sciences industry is gearing up for what analysts at PwC predict will be a highly active year for mergers and acquisitions in 2025, following a mixed performance in 2024. 13 December 2024
Pharmaceutical
The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended another batch medicines for approval at its December 2024 meeting, bringing the total number of medicines recommended for approval in 2024 to 114. 13 December 2024
Pharmaceutical
The Institute for Clinical and Economic Review (ICER) has published its annual report examining price increases for top-selling drugs in the USA, pointing to $815 million in prices hikes which it says are not clinically supported. 13 December 2024
Pharmaceutical
US biotech Corcept Therapeutics has reported positive results from the Phase IV CATALYST study of Korlym (mifepristone) in people with hypercortisolism and difficult-to-control type 2 diabetes. 13 December 2024
Pharmaceutical
Italy-based CNS specialist Newron Pharmaceuticals has entered into a license agreement with EA Pharma, part of Japan’s Eisai to develop, manufacture and commercialize Newron’s innovative modulator of the excessive release of glutamate, evenamide, in Japan and other designated territories. 13 December 2024
Pharmaceutical
US antivirals major Gilead Sciences announced that Dr Dietmar Berger will join the company on January 2, 2025, as chief medical officer (CMO) and will become a member of Gilead’s senior leadership team. Dr Berger succeeds Dr Merdad Parsey. 13 December 2024
Pharmaceutical
Spanish plasma-based medicines producer Grifols has announced the execution of an agreement for a private placement of 1.3 billion euros ($1.4 billion) of 7.125% senior secured notes due May 2030 at par. 13 December 2024
Pharmaceutical
Canada-headquartered Bausch + Lomb Corporation, a leading global eye health company, on Thursday confirmed reports that it is exploring a potential sale, acting in response to a request from the Canadian Investment Regulatory Organization (CIRO). 13 December 2024
Pharmaceutical
Based on its review of post-market clinical trial data, the US Food and Drug Administration (FDA) identified cases of serious liver injury among patients being treated for primary biliary cholangitis (PBC) with Ocaliva (obeticholic acid) who did not have cirrhosis of the liver. 13 December 2024
Pharmaceutical
UK-based Tenpoint Therapeutics and Seattle’s Visus Therapeutics have announced the completion of their merger to create an entirely new chapter in ophthalmic therapeutic medicines aimed at rejuvenating the aging eye. 12 December 2024
Pharmaceutical
A plan to buy back a whopping $15 billion worth of shares comes in at three times the previous largest scheme in Eli Lilly’s history. 12 December 2024
Pharmaceutical
Danish allergy immunotherapy specialist ALK Abello announced that its European regulatory filing for Acarizax (house dust mite sublingual allergy immunotherapy tablet) in young children aged five to 11 has been approved by the health authorities in 21 European Union (EU countries via a type II variation procedure. 12 December 2024
Pharmaceutical
US clinical-stage drug developer Keros Therapeutics’ shares plummeted more than 73% to $18.20 in pre-market activity on revealing a setback for a lead investigational candidate. 12 December 2024
Pharmaceutical
UK-based Essential Pharma has announced the completion of a 900 million euros ($945 million) financing. 12 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze